Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1453601 | 0.88 | HTR6 (0.40) | HTR6CYP11B1CYP11B2PTGS2 | |
| SCHEMBL1454242 | 0.81 | HTR6 (0.33) | HTR6 | |
| SCHEMBL1453055 | 0.81 | PTGS2 (0.37) | CYP11B1CYP11B2PTGS2 | |
| SCHEMBL1453622 | 0.81 | CYP11B2 (0.41) | CYP11B1CYP11B2PTGS2 | |
| SCHEMBL1453878 | 0.80 | CYP11B1 (0.32) | CYP11B1CYP11B2PTGS2 | |
| SCHEMBL1454536 | 0.76 | HTR6 (0.35) | HTR6 | |
| SCHEMBL1453298 | 0.76 | HTR2A (0.42) | HTR6 | |
| SCHEMBL1453518 | 0.75 | HTR6 (0.34) | HTR6 | |
| SCHEMBL1453738 | 0.75 | CYP11B2 (0.41) | CYP11B1CYP11B2PTGS2 | |
| SCHEMBL1453266 | 0.75 | HTR1A (0.41) | CYP11B1CYP11B2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910783-B2 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | SP1, TTL, TTLL12 | HTR6 3192/4885CYP11B1 1650/4885CYP11B2 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.